➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Baxter
Medtronic
AstraZeneca
Harvard Business School

Last Updated: October 25, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,022,106

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,022,106 protect, and when does it expire?

Patent 8,022,106 protects LYSTEDA and is included in one NDA.

This patent has eight patent family members in two countries.

Summary for Patent: 8,022,106
Title:Tranexamic acid formulations
Abstract: Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.
Inventor(s): Moore; Keith A. (Loveland, OH), Heasley; Ralph A. (Webster Grove, MO), Greiwe; Jeffrey S. (Ft. Thomas, KY), Facemire; John W. (Douglasville, GA), Modest; Jason D. (Minneapolis, MN)
Assignee: Ferring B.V. (Hoofddorp, NL)
Application Number:12/433,510
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,022,106
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Delivery; Use;

Drugs Protected by US Patent 8,022,106

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ferring Pharms Inc LYSTEDA tranexamic acid TABLET;ORAL 022430-001 Nov 13, 2009 AB RX Yes Yes   Start Trial   Start Trial TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,022,106

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan 2008508275   Start Trial
Japan 2008508276   Start Trial
Japan 2011168596   Start Trial
Japan 2014193878   Start Trial
Japan 5000504   Start Trial
Japan 5205053   Start Trial
World Intellectual Property Organization (WIPO) 2006023000   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Merck
Colorcon
McKinsey
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.